Neurometabolic Disorders Industry - Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies

| comments

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease. The report examines the treatment usage patterns and also includes insights into the R&D product pipeline and explores the competitive landscape including major players in neurometabolic disorders market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in neurometabolic disorders market.

Neurometabolic Disorders Industry

Published: March 2012
No. of Pages: 142
 
Scope
  • The report analyzes market characterization, pipeline analysis and key M&A trends in the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease markets in the neurometabolic disorders market.
  • Data and analysis on the contraceptives market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease in the neurometabolic disorders market from 2002 to 2010, with forecasts to 2017.
  • Market data on the therapeutic landscape which covers market revenues, treatment usage patterns and annual cost of therapy.
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the neurometabolic disorders market.
  • Key M&A activities and Licensing Agreements that took place from 2005 to 2011 in the contraceptives market.
Reasons to buy
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of the neurometabolic disorders market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
List of Figures
Figure 1: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts ($m), 2002-2017 15
Figure 2: Neurometabolic Disorders Market to 2017, Global, Annual Cost of Therapy ($), 2002-2017 16
Figure 3: Neurometabolic Disorders Market to 2017, Global, Treatment Usage Pattern, 2002-2017 17
Figure 4: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts, By Geography ($m), 2002-2017 20
Figure 5: Neurometabolic Disorders Market to 2017, The US, Revenue Forecasts ($m), 2002-2017 22
Figure 6: Neurometabolic Disorders Market to 2017, The US, Annual Cost of Therapy ($), 2002-2017 23
Figure 7: Neurometabolic Disorders Market to 2017, The US, Treatment Usage Pattern, 2002-2017 24
Figure 8: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017
Figure 9: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 28
Figure 10: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Treatment Usage Pattern, 2002-2017 29
Figure 11: Neurometabolic Disorders Market to 2017, Japan, Revenue Forecasts ($m), 2002-2017 31
Figure 12: Neurometabolic Disorders Market to 2017, Japan, Annual Cost of Therapy ($), 2002-2017 32
Figure 13: Neurometabolic Disorders Market to 2017, Japan, Treatment Usage Pattern, 2002-2017 33
Figure 14: Neurometabolic Disorders Market to 2017, Global, Gaucher’s Disease, Revenue Forecasts ($m), 2002-2017 36
Figure 15: Neurometabolic Disorders Market to 2017, Global, Gaucher’s Disease, Revenue Forecasts, By Geography ($m), 2002-2017 38
Figure 16: Neurometabolic Disorders Market to 2017, Global, Gaucher’s Disease, Annual Cost of Therapy ($), 2002-2017 40
Figure 17: Neurometabolic Disorders Market to 2017, Global, Gaucher’s Disease, Treatment Usage Pattern, 2002-2017 41
Share this article :

Post a Comment

 
Support : Creating Website | Johny Template | Mas Template
Copyright © 2011. Market Forecasts - All Rights Reserved
Template Created by Creating Website Published by Mas Template
Proudly powered by Blogger